目的 探討二十五味鬼臼丸聯(lián)合重組人干擾素α2a栓治療慢性宮頸炎的臨床療效。方法 回顧性分析2019年4月—2020年4月在鄭州頤和醫(yī)院治療的88例慢性宮頸炎患者的臨床資料，依據(jù)住院號末尾的奇偶分成對照組和治療組，每組各44例。對照組于經(jīng)期結束后睡前給予重組人干擾素α2a栓，置于陰道后穹窿，1枚/次，1次/2 d，1個月經(jīng)周期連用10次為1個療程；治療組在對照組基礎上口服二十五味鬼臼丸，2丸/次，2次/d。兩組患者均治療3個月。觀察兩組患者臨床療效，比較治療前后兩組患者臨床癥狀消失時間，陰道灌洗液中細胞因子白細胞介素1β（IL-1β）、IL-8、IL-17、IL-10和干擾素γ（IFN-γ）含量。結果 經(jīng)治療，治療組總有效率明顯高于對照組（97.73% vs 81.82%，P<0.05）。經(jīng)治療，治療組在陰道分泌物消失時間、創(chuàng)面愈合時間、外陰瘙癢消失時間、月經(jīng)周期恢復時間、下腹疼痛消失時間均明顯早于對照組（P<0.05）。經(jīng)治療，兩組陰道灌洗液中IL-1β、IL-8、IL-17水平均顯著下降，而IL-10、IFN-γ水平均升高（P<0.05），且治療組改善最顯著（P<0.05）。結論 二十五味鬼臼丸聯(lián)合重組人干擾素α2a栓治療慢性宮頸炎可有效改善患者臨床癥狀，降低炎性因子表達，具有一定的臨床推廣應用價值。

Objective To investigate the clinical efficacy of Ershiwuwei Guijiu Pills combined with Recombinant Human Interferon α2a Vaginal Suppository in treatment of chronic cervicitis. Methods The clinical data of 88 patients with chronic cervicitis treated in Zhengzhou Yihe Hospital from April 2019 to April 2020 were analyzed retrospectively. They were divided into control and treatment groups according to the odd and even number at the end of the hospitalization number, and each group had 44 cases. Patients in the control group were given Recombinant Human Interferon α2a Vaginal Suppository before bedtime after menstruation, which were placed in the posterior vaginal fornix, 1 suppository/time, twice daily, the treatments of 10 times in one menstrual cycle were as a course of treatment. Patients in the treatment group po administered with Ershiwuwei Guijiu Pills on the basis of the control group, 2 pills/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, and the disappearance time of clinical symptoms, the cytokine levels of IL-1β, IL-8, IL-17, IL-10, and IFN-γ in vaginal lavage fluid in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (97.73% vs 81.82%, P<0.05). After treatment, the disappearance time of vaginal discharge, wound healing, vulvar pruritus, menstrual cycle recovery, and lower abdominal pain in the treatment group were significantly earlier than that in the control group (P<0.05). After treatment, the expression of IL-1β, IL-8, and IL-17 in vaginal lavage fluid in two groups were significantly decreased, while the expression of IL-10 and IFN-γ were significantly increased (P<0.05), and the treatment group improved most significantly (P<0.05). Conclusion Ershiwuwei Guijiu Pills combined with Recombinant Human Interferon α2a Vaginal Suppository in treatment of chronic cervicitis can effectively improve the clinical symptoms and reduce the expression of inflammatory factors, which has a certain clinical application value.

R984